DRUG · Mapped RxNorm record
Pembrolizumab
Normalized identity: pembrolizumabView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer
NCT06407310
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Carboplatin
Normalized identity: carboplatinView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Paclitaxel
Normalized identity: paclitaxelView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedNeoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer
Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Triple Negative Breast Cancerunresolved
Interventions
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
CarboplatinDRUG · verified · RxNorm: carboplatin
PaclitaxelDRUG · verified · RxNorm: paclitaxel
Sponsors & collaborators
Tel Aviv Medical Centerlead sponsor
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06407310 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.